Octapharma USA Launches Co-Pay Program for Wilate
- By BSTQ Staff
Octapharma USA has launched the Octapharma Co-Pay Assistance Program available to von Willebrand’s disease patients who are currently receiving Wilate (von Willebrand factor/coagulation factor VIII complex [human]) or have a prescription to begin therapy. The new program offers eligible patients a maximum of $6,000 annually for co-pay, co-insurance and deductible expenses associated with their treatment without regard for their ability to pay. Patients must have third-party commercial insurance to participate in the program.
“We realize that patient out-of-pocket expenses associated with healthcare can sometimes be daunting; therefore, Octapharma has committed to support a program specifically designed to supplement these costs,” said Octapharma USA President Flemming Nielsen. To enroll in the program, eligible patients should contact the Octapharma Support Center at (800) 554-4440. The program is not available to patients who are covered under Medicaid, Medicare, MediGap, VA, DOD, Tricare or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program. Patients must be residents of the U.S.
